4D Pharmacueticals Produce Orally Delivered Live Biotherapeutics

Phase I Clinical Trial Generates Data on Mechanism of Action, Safety and Tolerability

4D pharma plc, a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following update on the phase 1 clinical trial in respect of Blautix, its proprietary single strain live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS).

Read more

The White House announces $121M-plus National Microbiome Initiative

Dr. George Gunn joins Diversigen Board of Directors

Dr. George Gunn joins Diversigen Board of Directors

Diversigen, Inc., today announced the appointment of Dr. George Gunn to the company’s Board of Directors. Dr. Gunn is renowned for his successful leadership and contributions to the global animal health and pharmaceutical industries. Until January 2015, Dr. Gunn was Division Head of Novartis Animal Health and a member of the Novartis Executive Committee.

Read more